The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
This order is subject to initial advance payment as per the agreed terms of the contract
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
Subscribe To Our Newsletter & Stay Updated
